trending Market Intelligence /marketintelligence/en/news-insights/trending/Bxt9ACEuMg4jPUxXAfpEdg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J acquires bladder disease therapy developer TARIS BioMedical

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

J&J acquires bladder disease therapy developer TARIS BioMedical

Johnson & Johnson acquired Lexington, Mass.-based private biotechnology company TARIS BioMedical Inc., which specializes in the development of a drug delivery technology to treat bladder diseases, including cancer.

TARIS will maintain its research operations in Lexington and will become a part of Janssen R&D's oncology therapeutic area, J&J noted in its Dec. 20 press release.

TARIS' lead product candidate TAR-200, uses the biotech's proprietary technology that allows the continuous release of a drug into the patient's bladder through a silicon-based device.

Janssen's oncology research program will use TARIS' technology to advance current experimental treatments and explore new candidates.

New Brunswick, N.J.-based J&J did not disclose the financial details of the transaction.